echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Monoclonal antibodies against MERS coronavirus show promise in phase I trials

    Monoclonal antibodies against MERS coronavirus show promise in phase I trials

    • Last Update: 2021-03-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A phase I clinical trial of a monoclonal antibody (mAb) for the treatment of Middle East Respiratory Syndrome (MERS) coronavirus found that the monoclonal antibodies REGN3048 and REGN3051 are well tolerated and safe.


    This study is the first human trial.


    In preclinical studies, researchers administered REGN3048 and REGN3051 to genetically modified mice (unlike wild-type mice, genetically modified mice can be infected with MERS CoV).


    Infection When administered the day before coronavirus exposure, both REGN3048 and REGN3051 can reduce the level of virus detected in the lungs.


    prevention

     

    Original source:

    Original source:

    https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.